Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics reports developments in genomic medicine, with a pipeline centered on neurological diseases, Fabry disease gene therapy, zinc finger epigenetic regulation, capsid discovery and modular integrase technology. Company updates commonly cover clinical and nonclinical data presentations, regulatory submissions for isaralgagene civaparvovec, or ST-920, in Fabry disease, and neurology programs such as small fiber neuropathy and chronic neuropathic pain.
Recurring news also includes financial results, earnings calls, collaboration and licensing activity around neurotropic capsids, and public-company matters affecting SGMO common stock. Listing-status announcements, including Nasdaq compliance and OTCQB quotation matters, form part of the company's corporate-status coverage alongside pipeline and technology updates.
Sangamo Therapeutics (OTCQB: SGMO) reported first quarter 2026 results and development updates. Consolidated net loss was $31.0 million ($0.08/share) versus $30.6 million ($0.14/share) a year ago, on revenue of $1.4 million versus $6.4 million.
The company is progressing a rolling BLA for ST-920 in Fabry disease, with preclinical/clinical modules submitted and its antibody assay companion diagnostic accepted for PMA review. Neurology programs advanced, including six activated sites in the Phase 1/2 STAND study of ST-503 and ongoing CTA-enabling work for ST-506 in prion disease. Cash and equivalents were $27.6 million, expected to fund operations into the third quarter of 2026. Sangamo’s shares began trading on the OTCQB Venture Market after a Nasdaq delisting determination, which the company plans to appeal.
Sangamo Therapeutics (OTCQB:SGMO) will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026. The company will host a public conference call at 4:30 p.m. Eastern that will review financial results and provide business updates, with access via online registration, webcast, and replay.
Sangamo Therapeutics (Nasdaq: SGMO) will present three abstracts at the 29th ASGCT Annual Meeting, May 11-15, 2026, in Boston and virtually. Presentations highlight neurology pipeline advances in zinc finger epigenetic regulation and updates on the protein-guided MINT modular integrase platform.
Two posters cover zinc finger repressors for Nav1.7 (small fiber neuropathy) and a BBB-penetrant prion protein repressor (nonhuman primate single-cell data). An oral presentation details modular integrase improvements at the TRAC locus and potential integration of large DNA payloads for diverse mutations.
Sangamo (NASDAQ: SGMO) announced its common stock will transition from The Nasdaq Capital Market to the OTCQB Venture Market at the open of trading on May 5, 2026, after receiving a Nasdaq notice related to minimum bid price non-compliance.
The company plans to request a hearing to appeal Nasdaq's delisting determination, has secured OTCQB quotation approval under the existing symbol SGMO, and says the transition is not expected to materially impact operations. Sangamo is pursuing additional capital and evaluating strategic options; details will be provided if definitive agreements are executed.
Sangamo Therapeutics (NASDAQ: SGMO) reported 4Q and full‑year 2025 results and business milestones on March 30, 2026. Key developments include a rolling BLA submission to the FDA for ST-920 under Accelerated Approval after positive STAAR topline eGFR data, Fast Track designation for ST-503, three STAC‑BBB capsid licenses (including Lilly), and clinical progress in neurology.
Financials: 4Q25 net loss $37.4M; FY25 net loss $122.9M; revenues $39.6M in 2025; cash $20.9M at year-end with runway into Q3 2026, subject to additional funding.
Sangamo Therapeutics (Nasdaq: SGMO) said it will release its fourth quarter and full year 2025 financial results after market close on Monday, March 30, 2026. A public conference call and webcast is set for 4:30 p.m. Eastern on March 30, 2026, followed by a replay available under Events.
Participants must register to receive dial‑in numbers and a unique passcode or use a dial‑out option; the live webcast link is on the company website in Investors and Media.
Sangamo Therapeutics (NASDAQ: SGMO) advanced a rolling Biologics License Application (BLA) submission to the U.S. FDA for isaralgagene civaparvovec (ST-920) for adults with Fabry disease on March 9, 2026. Sangamo has submitted preclinical and clinical modules and previously initiated the rolling submission in December 2025.
The company also submitted an antibody assay companion diagnostic to FDA CDRH seeking PMA. The STAAR registrational study showed a positive mean annualized eGFR slope at 52 weeks, which FDA agreed may serve as an endpoint to support accelerated approval.
Sangamo (NASDAQ: SGMO) reported detailed Phase 1/2 STAAR data for isaralgagene civaparvovec (ST-920) in Fabry disease, showing a positive mean annualized eGFR slope at 52 weeks and sustained α-Gal A activity up to 4.5 years.
The company initiated a rolling BLA submission to the FDA under the Accelerated Approval pathway, and the FDA agreed that 52-week mean annualized eGFR slope can serve as a primary basis for approval.
Sangamo Therapeutics (Nasdaq: SGMO) priced an underwritten offering to raise gross proceeds of approximately $25.0 million through the sale of 35,190,292 shares of common stock and pre-funded warrants to purchase 17,787,033 shares, together with accompanying warrants to purchase 52,977,325 shares.
Combined offering prices are $0.4719 per share plus warrant and $0.4619 per pre-funded warrant plus warrant. Accompanying warrants exercise at $0.4719, become exercisable six months after issuance and expire 5.5 years from issuance. Closing expected on or about February 4, 2026.
Sangamo Therapeutics (Nasdaq: SGMO) has initiated a rolling submission of a Biological License Application (BLA) to the U.S. FDA seeking accelerated approval for isaralgagene civaparvovec (ST-920) to treat adults with Fabry disease.
The registrational STAAR study showed a positive mean annualized eGFR slope at 52 weeks across dosed patients, and the FDA agreed that eGFR slope will serve as an endpoint to support accelerated approval. Sangamo expects to complete the BLA submission under the accelerated pathway in Q2 2026. ST-920 has received Orphan Drug, Fast Track, and RMAT designations from the FDA and regulatory recognitions from EMA and UK regulators.